Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
Mol Neurodegener. 2021 Jan 13;16(1):2. doi: 10.1186/s13024-021-00424-9.
Successful development of agents that improve cognition and behavior in Alzheimer's disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder.
There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6 cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of insomnia, psychosis, apathy, and agitation in AD. There are currently 4 AD-related psychotropic agents in Phase 2 trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial conduct for symptomatic treatment of AD.
Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.
成功开发改善阿尔茨海默病（AD）认知和行为的药物对于改善表现出这种进行性疾病症状的患者的生活至关重要。
最近没有批准用于 AD 的认知增强药物。目前有 6 种认知增强剂处于 2 期临床试验，4 种处于 3 期临床试验。它们代表了多种新的机制。随着治疗失眠、精神病、淡漠和激越的进展，在治疗 AD 的神经精神症状方面取得了进展。目前有 4 种与 AD 相关的精神药物处于 2 期临床试验，7 种处于 3 期临床试验。许多新的机制正在被探索用于治疗认知和行为靶点。临床试验设计、结局测量和人群定义方面的进展正在改善 AD 症状治疗的临床试验。
开发用于 AD 的认知和行为症状的新药物的进展，加上改进的试验方法，有望满足 AD 患者改善认知和减轻神经精神症状的未满足需求。
